You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 27, 2025

Drug Price Trends for SM INFANT PAIN-FEVER


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for SM INFANT PAIN-FEVER

Average Pharmacy Cost for SM INFANT PAIN-FEVER

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug NameNDCPrice/Unit ($)UnitDate
SM INFANT PAIN-FEVER 160 MG/5 49348-0430-30 0.05438 ML 2025-04-23
SM INFANT PAIN-FEVER 160 MG/5 49348-0430-30 0.05449 ML 2025-03-19
SM INFANT PAIN-FEVER 160 MG/5 49348-0430-30 0.05492 ML 2025-02-19
>Drug Name>NDC>Price/Unit ($)>Unit>Date
Showing 1 to 3 of 3 entries

Market Analysis and Price Projections for Infant Pain and Fever Medications

Introduction to Infant Pain and Fever Medications

Infant pain and fever medications are a crucial segment of the pharmaceutical market, particularly within the antipyretic and analgesic drug categories. These medications, such as acetaminophen and ibuprofen, are widely used to treat common childhood ailments like fever, pain, and discomfort.

Market Size and Growth

The global market for antipyretic drugs for children has been experiencing significant growth. As of 2023, the market size was valued at $3.02 billion and is projected to grow to $3.21 billion in 2024, with a compound annual growth rate (CAGR) of 6.4%[3].

By 2028, the market is expected to reach $4.16 billion, driven by factors such as increased awareness of pediatric health, a growing incidence of fever-related illnesses, and rising healthcare expenditures among families. The expansion of pharmaceutical companies into emerging markets and advancements in drug formulations also contribute to this growth[3].

Key Drivers of the Market

Heightened Awareness of Pediatric Health

There is a growing emphasis on pediatric health, leading to increased demand for antipyretic medications. Parents are becoming more proactive in seeking medical treatments for their children, driving the market forward[3].

Growing Incidence of Fever-Related Illnesses

The prevalence of viral infections and other fever-related illnesses in children is on the rise, which increases the need for effective antipyretic treatments. This trend is particularly evident in both developed and developing countries[3].

Advances in Drug Formulations

Technological innovations in pediatric drug formulations are enhancing the efficacy and safety of antipyretic medications. New formulations and delivery mechanisms, such as easier-to-administer liquids and tablets, are making these drugs more accessible and user-friendly[3].

Government Initiatives

Government initiatives aimed at improving access to pediatric healthcare in developing countries are also driving the market. These initiatives often include subsidies and programs to make essential medications more affordable and widely available[3].

Competitive Landscape

The market for infant pain and fever medications is highly competitive, with several major players. Here are a few key competitors:

KinderFarms, LLC

KinderFarms, LLC, recently faced a voluntary recall of their KinderMed Pain & Fever products due to acetaminophen instability. This incident highlights the importance of quality control and regulatory compliance in the industry[1].

CVS Health

CVS Health offers its own brand of infants' pain and fever medications, which are widely available in their stores and online. Their products are part of the broader market competition, offering consumers a range of choices[2].

Price Projections

The pricing of infant pain and fever medications can vary based on several factors, including the brand, formulation, and distribution channels.

Current Pricing Trends

As of now, the prices of these medications are relatively stable, with over-the-counter (OTC) options generally priced between $5 to $15 per unit, depending on the brand and size of the product[2].

Future Pricing Projections

Given the projected market growth and increasing demand, prices may remain competitive but could see a slight increase due to rising production costs and advancements in formulations. However, regulatory pressures and competition are likely to keep prices in check.

Technological Innovations and Trends

Natural and Herbal-Based Antipyretics

There is a growing trend towards natural and herbal-based antipyretic drugs for children. Parents are increasingly seeking alternatives to traditional medications, driving innovation in this area[3].

Personalized Treatments

There is an increasing emphasis on personalized treatments for managing fevers in children. This includes tailored dosages and formulations based on individual needs, which could impact pricing and market dynamics[3].

Telemedicine and Remote Consultations

The adoption of telemedicine platforms is making it easier for parents to access pediatric consultations related to fever management. This trend could influence how medications are prescribed and used, potentially affecting market prices and distribution channels[3].

Safety and Efficacy

Acetaminophen vs. Ibuprofen

Studies have shown that both acetaminophen and ibuprofen are effective for treating children's pain and fever, with ibuprofen being slightly superior as an antipyretic. However, both drugs have their own safety profiles and potential side effects, which must be carefully considered by parents and healthcare providers[5].

Consumer Behavior and Preferences

Brand Loyalty and Trust

Consumers often prefer well-known and trusted brands when it comes to their children's health. Brand loyalty plays a significant role in the market, with parents often sticking to brands they trust and have used before[2].

Convenience and Accessibility

The convenience of purchasing these medications, whether online or in-store, is a key factor. Consumers appreciate easy access to these products, which can influence their purchasing decisions[2].

Regulatory Environment

The regulatory environment for infant pain and fever medications is stringent, with recalls like the one by KinderFarms, LLC, highlighting the importance of compliance. Manufacturers must ensure that their products meet all safety and efficacy standards set by regulatory bodies such as the U.S. Food and Drug Administration (FDA)[1].

Key Takeaways

  • The global market for antipyretic drugs for children is growing, driven by increased awareness of pediatric health and technological advancements.
  • Prices are expected to remain competitive but may see slight increases due to rising production costs and innovations.
  • Natural and herbal-based antipyretics, personalized treatments, and telemedicine are emerging trends.
  • Safety and efficacy of medications like acetaminophen and ibuprofen are critical, with ongoing research needed to optimize their use.
  • Consumer behavior is influenced by brand loyalty, convenience, and accessibility.

FAQs

Q: What is the current market size for antipyretic drugs for children? A: As of 2023, the market size for antipyretic drugs for children is valued at $3.02 billion[3].

Q: Which factors are driving the growth of the antipyretic drugs market for children? A: The growth is driven by heightened awareness of pediatric health, a growing incidence of fever-related illnesses, and advancements in drug formulations, among other factors[3].

Q: What are the potential side effects of acetaminophen instability in infant pain and fever medications? A: Acetaminophen instability can lead to acute adverse health effects, including abdominal pain, nausea, vomiting, or jaundice at higher doses[1].

Q: How do ibuprofen and acetaminophen compare in terms of efficacy and safety for treating children's pain and fever? A: Both ibuprofen and acetaminophen are effective, but ibuprofen is slightly superior as an antipyretic. Both have their own safety profiles and potential side effects[5].

Q: What trends are expected to shape the future of the infant pain and fever medications market? A: Trends include a shift towards natural and herbal-based antipyretics, personalized treatments, and the adoption of telemedicine platforms[3].

Sources

  1. FDA: KinderFarms, LLC Voluntarily Recalling all KinderMed Pain & Fever Products Due to Acetaminophen Instability.
  2. CVS Health: CVS Health Infants' Pain & Fever, 2 OZ.
  3. Global Industry Analysts Research: Antipyretic Drugs For Children Global Market Report 2024.
  4. Allied Market Research: Pain Management Drugs Market Size, Share | Forecast - 2033.
  5. JAMA Network: Efficacy and Safety of Acetaminophen vs Ibuprofen for Treating Children's Pain or Fever.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.